Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

298.66 +1.53 (+0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Tuesday Talk: Action!
U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Sage Therapeutics (SAGE) Stock Is Falling Despite Meeting Primary Endpoint In Major Depressive Disorder Trial With Zuranolone
Looking to make a comeback after a big Phase 3 flop, Sage Therapeutics Inc (NASDAQ: SAGE) revealed data from another Phase 3 evaluating zuranolone in patients with... 
Via Benzinga
Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced data from WATERFALL Phase 3 study evaluating zuranolone (SAGE-217/... 
Via Benzinga
These 3 Words From the FDA Ensure the Biogen Drama Is Far From Over
Although the company's Alzheimer's drug got approval from the agency, that doesn't mean you should rush out and buy this risky stock. 
Via The Motley Fool
Exposures Product Safety
Why Biogen Shares Are Trading Higher Today
Biogen Inc (NASDAQ:BIIB) shares are trading higher by 3.2%... 
Via Benzinga
Biogen Sinks Despite Raft of Analyst Upgrades
The Aduhelm effect seems to be quickly wearing off the stock. 
Via The Motley Fool
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 14) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Yet Another Biogen's Retinal Disease Gene Therapy Fails In Late-Stage Study
While basking in the glow of the approval for its Alzheimer’s treatment, Biogen Inc (NASDAQ: BIIB) announced that a gene therapy candidate for eye disease... 
Via Benzinga
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in the form of approval... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Takeda, Blueprint Medicines, Orphazyme, Eton On The Radar Ahead Of FDA Decisions, IPOs
Biotech stocks extended their gains in the week ended June 11, supported by the broader market strength and some stock-specific moves. The biggest biotech news of the week came in... 
Via Benzinga
Exposures Product Safety
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
The Latest Barron's Picks And Pans: DocuSign, UPS, Taiwan Semiconductor And More
The cover story in this weekend's Barron's examines how teenage traders are shaking up the market. Other featured articles discuss which drugmakers benefit from a new... 
Via Benzinga
After a 50% Gain, Is It Too Late to Buy Biogen?
The coming months will offer important clues about long-term revenue. 
Via The Motley Fool
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Biogen isn't the only company whose shares should benefit from a breakthrough drug. 
Via The Motley Fool
Bulls And Bears Of The Week: Apple, Amazon, Biogen, Bitcoin, Tesla And More
Via Talk Markets
Benzinga's Bulls And Bears Of The Week: Apple, Amazon, Biogen, Bitcoin, Tesla And More
Benzinga has examined the prospects for many investor favorite stocks over the pas... 
Via Benzinga
Nvidia And Dollar Tree Lead The Nasdaq In A Mixed Day For The Markets
U.S. indices had another mixed day of trading following worse-than-expected U.S. jobless figures and inflation data released Thursday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
BIIB Stock: 9 Things to Know About Biogen’s Alzheimer Drug Approval Controversy
Biogen (BIIB) stock is dipping lower today on the additional controversy surrounding the approval of its Alzheimer’s drug, Aduhelm. 
Via InvestorPlace
Thinking About Buying Stock Or Options In Tilray, Ocugen, Biogen Or Snowflake?
One of the most common questions traders have about stocks is “Why Is It Moving?” That’s why Benzinga created the Why I... 
Via Benzinga
Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments
Data doesn't lie. These companies have the potential to quickly steal the spotlight. 
Via The Motley Fool
Exposures Product Safety
S&P 500 Hits Record High; Biogen Alzheimer's Drug, Tesla, Apple, RH, GameStop In Focus: Weekly Review
The S&P 500 hit a new high this week. The FDA OK'd a Biogen Alzheimer's drug. Tesla, Apple, RH, GameStop were in focus. 
Via Investor's Business Daily
Topics Stocks
Exposures Product Safety US Equities
With Aduhelm Approval Behind Biogen, 5 Catalysts For Investors To Watch
Biogen Inc. (NASDAQ: BIIB) made history of sorts with the FDA approval for its Alzheimer's treatment Aduhelm. Notwithstanding the still-raging debate over the decision, an... 
Via Benzinga
Exposures Product Safety
Why Biogen, Lilly, and Prothena Stocks Soared This Week
The FDA's approval of Biogen's Aduhelm in treating Alzheimer's disease boosted all three stocks. 
Via The Motley Fool
Exposures Product Safety
What 12 Analyst Ratings Have To Say About Biogen
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2 0 0 Somewhat... 
Via Benzinga
Biogen Gets an Unearned Rip on an Unproven Drug
Biogen will charge $56,000 for Aduhelm, although there's no guarantee it will work against Alzheimer's. That makes BIIB stock risky. 
Via InvestorPlace
Juvenile Investing Mob
Tech stocks did well in Europe but not in the US. The data are unconvincing. 
Via Talk Markets
Senator Takes Aim at Biogen's New Alzheimer's Drug
Sen. Ron Wyden calls Aduhelm's $56,000 price tag "unconscionable." 
Via The Motley Fool
Where Biogen Stands With Analysts
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 2 0 0 0 Somewhat... 
Via Benzinga
A Biotech ETF For Aggressive, Risk-Tolerant Investors
The biotechnology sector has been on fire thanks to news from Biogen Inc. (NASDAQ: BIIB). The FDA approved its controverisal drug that can treat Alzheimer’s Disease. Not... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.